Constitutive activation of the MAPK pathway results from gain-of-function mutations in genes encoding pathway constituents, particularly NRAS, a common finding in up to 11% of patients with acute myeloid leukemia (AML) [3,4,5]. Here, NRAS is linked to acute myeloid leukemia.